Abstract:Purpose/Objective(s)Using a novel bioinformatics strategy, we tested whether single nucleotide polymorphisms (SNPs) are predictive of adverse genitourinary (GU) and/or gastrointestinal (GI) late reactions in men treated for prostate cancer in a randomized clinical trial.Materials/MethodsThere were 303 evaluable patients in the parent cohort of the randomized trial, performed from 2002 to 2006 at Fox Chase Cancer Center. There were 124 in whom DNA from peripheral blood lymphocytes and the full de-archived 3D treatment plans were available. SNPs were processed using the HumanOmni2.5-4v1_C beadchip (Illumina, Inc.), which detects 2.5 million individual SNPs. SNP status was correlated to the maximum late gastrointestinal (GI) or genitourinary (GU) toxicity in follow-up: Grade 0 (n = 25) vs. Grade 1 or greater (n = 94). A novel bioinformatics method was used to filter SNPs likely to be related to toxicity, based on a complete survey of the literature to identify genes shown to be related to radioresponse (∼200 papers resulting in 220 unique genes). In addition, two publicly available mRNA microarray datasets were re-analyzed to identify genes modulated by radiation. Common genes (20) were input into the MetaCore software system, which identified a key protein interaction network consisting of seven highly linked genes: MYC, GADD45A, PPM1D, BBC3, CDKN1A, PLK3, and XPC, resulting in 81 SNPs we tested further. To build predictive models, we used linear discriminant analysis (LDA) and employed 10-fold cross validation. We report odds ratios (OR), the area under the receiver operating characteristic curve (AUC), and Matthew's correlation coefficient (r). SNP significance was tested using a permutation t test and the Bonferroni multiple comparison correction (81 comparisons).ResultsThe most statistically significant SNP was rs2032809 (OR = 0.39; Bonferroni-corrected p value = 0.025), within the BBC3 gene, which has been reported as a suppressor of apoptosis. The second most highly correlated SNP did not reach significance after Bonferroni correction, but was also within the BBC3 gene (rs10407441) (OR = 4.01; corrected p value = 0.14). No predictive models performed better than using the top SNP alone in LDA, resulting (on cross validation) in r = 0.37, and AUC = 0.67. Dosimetric variables, including normal tissue complication probability models for rectal and bladder toxicity, did not add predictive power to this model.ConclusionsThis is the first analysis of genetic factors related to GI and GU toxicity in a cohort of men treated relatively uniformly with external beam radiotherapy in a randomized trial. The novel bioinformatics strategy helped identify a statistically significant SNP that may help predict toxicity. Purpose/Objective(s)Using a novel bioinformatics strategy, we tested whether single nucleotide polymorphisms (SNPs) are predictive of adverse genitourinary (GU) and/or gastrointestinal (GI) late reactions in men treated for prostate cancer in a randomized clinical trial. Using a novel bioinformatics strategy, we tested whether single nucleotide polymorphisms (SNPs) are predictive of adverse genitourinary (GU) and/or gastrointestinal (GI) late reactions in men treated for prostate cancer in a randomized clinical trial. Materials/MethodsThere were 303 evaluable patients in the parent cohort of the randomized trial, performed from 2002 to 2006 at Fox Chase Cancer Center. There were 124 in whom DNA from peripheral blood lymphocytes and the full de-archived 3D treatment plans were available. SNPs were processed using the HumanOmni2.5-4v1_C beadchip (Illumina, Inc.), which detects 2.5 million individual SNPs. SNP status was correlated to the maximum late gastrointestinal (GI) or genitourinary (GU) toxicity in follow-up: Grade 0 (n = 25) vs. Grade 1 or greater (n = 94). A novel bioinformatics method was used to filter SNPs likely to be related to toxicity, based on a complete survey of the literature to identify genes shown to be related to radioresponse (∼200 papers resulting in 220 unique genes). In addition, two publicly available mRNA microarray datasets were re-analyzed to identify genes modulated by radiation. Common genes (20) were input into the MetaCore software system, which identified a key protein interaction network consisting of seven highly linked genes: MYC, GADD45A, PPM1D, BBC3, CDKN1A, PLK3, and XPC, resulting in 81 SNPs we tested further. To build predictive models, we used linear discriminant analysis (LDA) and employed 10-fold cross validation. We report odds ratios (OR), the area under the receiver operating characteristic curve (AUC), and Matthew's correlation coefficient (r). SNP significance was tested using a permutation t test and the Bonferroni multiple comparison correction (81 comparisons). There were 303 evaluable patients in the parent cohort of the randomized trial, performed from 2002 to 2006 at Fox Chase Cancer Center. There were 124 in whom DNA from peripheral blood lymphocytes and the full de-archived 3D treatment plans were available. SNPs were processed using the HumanOmni2.5-4v1_C beadchip (Illumina, Inc.), which detects 2.5 million individual SNPs. SNP status was correlated to the maximum late gastrointestinal (GI) or genitourinary (GU) toxicity in follow-up: Grade 0 (n = 25) vs. Grade 1 or greater (n = 94). A novel bioinformatics method was used to filter SNPs likely to be related to toxicity, based on a complete survey of the literature to identify genes shown to be related to radioresponse (∼200 papers resulting in 220 unique genes). In addition, two publicly available mRNA microarray datasets were re-analyzed to identify genes modulated by radiation. Common genes (20) were input into the MetaCore software system, which identified a key protein interaction network consisting of seven highly linked genes: MYC, GADD45A, PPM1D, BBC3, CDKN1A, PLK3, and XPC, resulting in 81 SNPs we tested further. To build predictive models, we used linear discriminant analysis (LDA) and employed 10-fold cross validation. We report odds ratios (OR), the area under the receiver operating characteristic curve (AUC), and Matthew's correlation coefficient (r). SNP significance was tested using a permutation t test and the Bonferroni multiple comparison correction (81 comparisons). ResultsThe most statistically significant SNP was rs2032809 (OR = 0.39; Bonferroni-corrected p value = 0.025), within the BBC3 gene, which has been reported as a suppressor of apoptosis. The second most highly correlated SNP did not reach significance after Bonferroni correction, but was also within the BBC3 gene (rs10407441) (OR = 4.01; corrected p value = 0.14). No predictive models performed better than using the top SNP alone in LDA, resulting (on cross validation) in r = 0.37, and AUC = 0.67. Dosimetric variables, including normal tissue complication probability models for rectal and bladder toxicity, did not add predictive power to this model. The most statistically significant SNP was rs2032809 (OR = 0.39; Bonferroni-corrected p value = 0.025), within the BBC3 gene, which has been reported as a suppressor of apoptosis. The second most highly correlated SNP did not reach significance after Bonferroni correction, but was also within the BBC3 gene (rs10407441) (OR = 4.01; corrected p value = 0.14). No predictive models performed better than using the top SNP alone in LDA, resulting (on cross validation) in r = 0.37, and AUC = 0.67. Dosimetric variables, including normal tissue complication probability models for rectal and bladder toxicity, did not add predictive power to this model. ConclusionsThis is the first analysis of genetic factors related to GI and GU toxicity in a cohort of men treated relatively uniformly with external beam radiotherapy in a randomized trial. The novel bioinformatics strategy helped identify a statistically significant SNP that may help predict toxicity. This is the first analysis of genetic factors related to GI and GU toxicity in a cohort of men treated relatively uniformly with external beam radiotherapy in a randomized trial. The novel bioinformatics strategy helped identify a statistically significant SNP that may help predict toxicity.

Abstract:Purpose/Objective(s)Gene expression signature for predicting radiosensitivity has been developed to subclassify tumor characteristics. Recently, a radiosensitivity gene signature, which includes 31 genes derived by integrating four different microarray experiments, has been found to have a potential for predicting radiosensitivity of cancer cells, but it was seldom validated in clinical cancer samples. In our study, we proposed that the gene signature may serve as a predictive biomarker for estimating the overall survival of radiation-treated patients. The significance of gene signature was tested in independent datasets with The Cancer Genome Atlas (TCGA), which is the most powerful cancer information database in the world.Materials/MethodsWe downloaded the mRNA expression profiling of the 16 different cancer types and corresponding clinical information from TCGA. After filtering out cancer types without radiation therapy information or insufficient clinical survival information, the 31 gene signature was applied to three independent datasets: glioblastoma multiforme (GBM), low-grade glioma (LGG), and head and neck squamous cell carcinoma (HNSCC). There were a total of 708 samples treated with radiation therapy, including 465 patients with GBM, 92 patients with HNSCC, and 151 patients with LGG, respectively. The patients were stratified into radiosensitive (RS) and radioresistant (RR) groups according to the above-mentioned 31-gene signature. The Kaplan-Meier method was used to estimate survival time and multivariate analysis was carried out using Cox proportional hazard model.ResultsAll the RT-treated patients were stratified into radiosensitive (RS) and radioresistant (RR) groups according to radiosensitivity gene signature. Patients assigned to RS group had an improved overall survival compared with RR group in GBM (median survival days: RS vs RR, 562 d vs 448 d, p = 0.001, HR = 1.568, 95% CI = 1.207-2.038) and HNSCC (median survival days: RS vs RR, 3314 d vs 2318 d, p = 0.004, HR = 3.960, 95% CI = 1.447-10.833) cohorts. The gene radiosensitivity gene signature has been proved to be an independent predictor, when considering age, KPS, molecular subtype, and additional chemotherapy as covariates for GBM (p = 0.015), and age and pathologic stage for HNSCC (p = 0.020). No significant difference of survival time was observed between the predicted RS and RR patients with LGG (p = 0.128).ConclusionsThis is the first study to use a radiosensitivity gene signature model to predict radiation-treated patients’ prognostic in three independent cohorts from TCGA. Although promising, this model needed to be further clinically validated in the routine diagnostic of GBM and HNSCC for an optimal treatment decision. Purpose/Objective(s)Gene expression signature for predicting radiosensitivity has been developed to subclassify tumor characteristics. Recently, a radiosensitivity gene signature, which includes 31 genes derived by integrating four different microarray experiments, has been found to have a potential for predicting radiosensitivity of cancer cells, but it was seldom validated in clinical cancer samples. In our study, we proposed that the gene signature may serve as a predictive biomarker for estimating the overall survival of radiation-treated patients. The significance of gene signature was tested in independent datasets with The Cancer Genome Atlas (TCGA), which is the most powerful cancer information database in the world. Gene expression signature for predicting radiosensitivity has been developed to subclassify tumor characteristics. Recently, a radiosensitivity gene signature, which includes 31 genes derived by integrating four different microarray experiments, has been found to have a potential for predicting radiosensitivity of cancer cells, but it was seldom validated in clinical cancer samples. In our study, we proposed that the gene signature may serve as a predictive biomarker for estimating the overall survival of radiation-treated patients. The significance of gene signature was tested in independent datasets with The Cancer Genome Atlas (TCGA), which is the most powerful cancer information database in the world. Materials/MethodsWe downloaded the mRNA expression profiling of the 16 different cancer types and corresponding clinical information from TCGA. After filtering out cancer types without radiation therapy information or insufficient clinical survival information, the 31 gene signature was applied to three independent datasets: glioblastoma multiforme (GBM), low-grade glioma (LGG), and head and neck squamous cell carcinoma (HNSCC). There were a total of 708 samples treated with radiation therapy, including 465 patients with GBM, 92 patients with HNSCC, and 151 patients with LGG, respectively. The patients were stratified into radiosensitive (RS) and radioresistant (RR) groups according to the above-mentioned 31-gene signature. The Kaplan-Meier method was used to estimate survival time and multivariate analysis was carried out using Cox proportional hazard model. We downloaded the mRNA expression profiling of the 16 different cancer types and corresponding clinical information from TCGA. After filtering out cancer types without radiation therapy information or insufficient clinical survival information, the 31 gene signature was applied to three independent datasets: glioblastoma multiforme (GBM), low-grade glioma (LGG), and head and neck squamous cell carcinoma (HNSCC). There were a total of 708 samples treated with radiation therapy, including 465 patients with GBM, 92 patients with HNSCC, and 151 patients with LGG, respectively. The patients were stratified into radiosensitive (RS) and radioresistant (RR) groups according to the above-mentioned 31-gene signature. The Kaplan-Meier method was used to estimate survival time and multivariate analysis was carried out using Cox proportional hazard model. ResultsAll the RT-treated patients were stratified into radiosensitive (RS) and radioresistant (RR) groups according to radiosensitivity gene signature. Patients assigned to RS group had an improved overall survival compared with RR group in GBM (median survival days: RS vs RR, 562 d vs 448 d, p = 0.001, HR = 1.568, 95% CI = 1.207-2.038) and HNSCC (median survival days: RS vs RR, 3314 d vs 2318 d, p = 0.004, HR = 3.960, 95% CI = 1.447-10.833) cohorts. The gene radiosensitivity gene signature has been proved to be an independent predictor, when considering age, KPS, molecular subtype, and additional chemotherapy as covariates for GBM (p = 0.015), and age and pathologic stage for HNSCC (p = 0.020). No significant difference of survival time was observed between the predicted RS and RR patients with LGG (p = 0.128). All the RT-treated patients were stratified into radiosensitive (RS) and radioresistant (RR) groups according to radiosensitivity gene signature. Patients assigned to RS group had an improved overall survival compared with RR group in GBM (median survival days: RS vs RR, 562 d vs 448 d, p = 0.001, HR = 1.568, 95% CI = 1.207-2.038) and HNSCC (median survival days: RS vs RR, 3314 d vs 2318 d, p = 0.004, HR = 3.960, 95% CI = 1.447-10.833) cohorts. The gene radiosensitivity gene signature has been proved to be an independent predictor, when considering age, KPS, molecular subtype, and additional chemotherapy as covariates for GBM (p = 0.015), and age and pathologic stage for HNSCC (p = 0.020). No significant difference of survival time was observed between the predicted RS and RR patients with LGG (p = 0.128). ConclusionsThis is the first study to use a radiosensitivity gene signature model to predict radiation-treated patients’ prognostic in three independent cohorts from TCGA. Although promising, this model needed to be further clinically validated in the routine diagnostic of GBM and HNSCC for an optimal treatment decision. This is the first study to use a radiosensitivity gene signature model to predict radiation-treated patients’ prognostic in three independent cohorts from TCGA. Although promising, this model needed to be further clinically validated in the routine diagnostic of GBM and HNSCC for an optimal treatment decision.

Identification Of A Single Nucleotide Polymorphism Related To Late Toxicity In A Randomized Hypofractionation Trial For Prostate Cancer

Single Nucleotide Polymorphism of the TGF-B1 T869C Gene Associates Risks of Treatment Related Pneumonitis and Distant Metastasis in Patients with Non–small-cell Lung Cancer Treated with Definitive Radiotherapy

Validation Of A Radiosensitivity Gene Signature In Radiation Therapy-Treated Patients From The Cancer Genome Atlas (Tcga)

Op-jnci190078 1..12

Gene polymorphism and prediction of toxicity to platinum-based chemotherapy in patients with gynecologic cancer

Abstract P3-19-29: Polygenic Risk Scores Predict Toxicities in Racially Diverse Breast Cancer Patients Following Radiotherapy

TGF-β1 Gene Polymorphisms Are Not Associated with Risk of Radiation-induced Pneumonitis in Chinese

Abstract 4582: Genome-wide Association Study of Toxicity Following Definitive Radiotherapy in Non-Small Cell Lung Cancer Patients.

Evaluation of Single Nucleotide Polymorphisms (SNP) in the P53 Binding Protein Gene (TP53BP1), in Breast Cancer Patients Treated with Breast Conserving Surgery and Whole-breast Irradiation (BCS+RT)

Association Between Single Nucleotide Polymorphisms (Snps) And Toxicity Of Advanced Non-Small-Cell Lung Cancer Patients Treated With Chemotherapy

The Predictive Role of MTHFR and ABCG2 Single Nucleotide Polymorphisms on the Outcome of Advanced Colorectal Cancer Treated with First-Line Chemotherapy

A Study of Ethnic Differences in TGFβ1 Gene Polymorphisms and Effects on the Risk of Radiation Pneumonitis in Non–Small-Cell Lung Cancer

Polymorphisms of BMP4 and HIF-1A Are Associated with Patient-Reported Symptoms in Non-Small-Cell Lung Cancer Patients Treated with Definitive Chemoradiation Therapy

Evaluation of Single Nucleotide Polymorphisms (snps) in the P53 Binding Protein 1 (TP53BP1) Gene in Breast Cancer Patients Treated with Breast-Conserving Surgery and Whole-Breast Irradiation (BCS + RT)

Incorporating Snps As Biomarkers to Improve the Fit of the Lyman Model for Radiation Pneumonitis

Single Nucleotide Polymorphism of Sod2 to Predict Survival for Chinese Gastric Cancer Patients Received Platinum/Fluorouracil-Based Adjuvant Chemotherapy

The Association Between the ERCC1/2 Polymorphisms and Radiotherapy Efficacy in 87 Patients with Non-Small Cell Lung Cancer.

Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy

Abstract 3626: Inflammation-related Genetic Variants Predict Radiation-Induced Toxicity Following Definitive Radiotherapy for Non-Small Cell Lung Cancer.

TGFβ1 Gene Polymorphisms with the Risk of Radiation Pneumonitis in Non-Small Cell Lung Cancer in Different Ethnic Study.

Abstract 77: Genetic Variations in the Stem Cell Pathway Predict for Toxicity Following Radiotherapy in Lung Cancer.